Alpha Tau Medical Limited, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (Nasdaq: HCCC), a special purpose acquisition company, have announced they have entered into a definitive business combination agreement. The transaction represents an implied pro forma equity value of approximately US$1 billion and is expected to provide up to US$367 million in gross proceeds, including up to US$275 million of cash held in the trust account of Healthcare Capital Corp. and a US$92 million PIPE. Upon closing of the Business Combination, Alpha Tau is expected to be listed on the Nasdaq. Latham & Watkins LLP represents Alpha Tau in the deSPAC transaction with an M&A team led by New York partner Eyal Orgad and New York counsel Michael Vardanian, with New York associates Serena Shi and Charles Shier, and a capital markets team led by London partner Joshua Kiernan and New York partner Nathan Ajiashvili, with New York counsel Michael Rosenberg and Houston associate Danny Shulman. Advice was provided on tax matters by Los Angeles/Century City partner Pardis Zomorodi, with New York associate Sam Yang.~~